Compare Summit Therapeutics Inc (SMMT) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Clear Secure Inc — how do they compare? Summit Therapeutics Inc trades at $17.59 (market cap $13.71B), while Clear Secure Inc trades at $43.43 (market cap $4.44B). The key difference: Summit Therapeutics Inc is far larger — about 3.1× Clear Secure Inc's market cap, and Clear Secure Inc pays a 1.33% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Clear Secure Inc for 19 Days on average.
| SMMT | YOU | |
|---|---|---|
Market Cap | $13.71B | $4.44B |
Volume | 6,173,057 | 1,477,828 |
Sector | Health | Technology |
52-Week High | $26.38 | $62.36 |
52-Week Low | $12.43 | $29.61 |
Typical Hold Time | 16 Days | 19 Days |
Enterprise Value | $13.04B | $3.59B |
Dividend Yield | — | 1.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.17, down 4.35% on the day, amid mixed technical signals with a bullish moving average trend but neutral oscillators. The company reported no revenue in 2025 and a net loss of $1.08 billion, with negative ROE and ROA, yet maintains a high P/B ratio of 21.76. Recent positive sentiment is driven by a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations for its lead drug ivonescimab, as reported by Reuters and Business Wire on September 28-29, 2026.
The outlook hinges on clinical success; upside exists if ivonescimab trials meet endpoints, supported by strong analyst consensus (65% buy rating) and a $29.33 price target. Key risks include cash burn from negative operating cash flow, drug development failures, and reliance on partnership outcomes, posing significant volatility for investors despite institutional interest.
Clear Secure (YOU) trades at $43.08, up 1.17% with strong fundamentals including 27% revenue growth and expanding profitability. The stock shows mixed technical signals with bullish overall momentum but overbought RSI levels. Recent Q2 earnings beat expectations with $0.49 EPS versus $0.40 estimate, while analyst consensus targets $61.40 representing 43% upside potential.
Outlook remains positive with accelerating membership growth and new corporate partnerships driving expansion. Key risks include competitive pressure in identity verification and potential execution challenges. The stock offers growth exposure but requires monitoring of technical overbought conditions and quarterly execution against elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
